MedPath

Sunrise Pharmaceutical Inc

Sunrise Pharmaceutical Inc logo
🇺🇸United States
Ownership
Private
Employees
11
Market Cap
-
Website
https://sunrisetherapytt.com

Clinical Trials

3

Active:0
Completed:3

Trial Phases

1 Phases

Not Applicable:3

Drug Approvals

8

FDA:8

Drug Approvals

DEXTROAMPHETAMINE SULFATE

Approval Date
Nov 16, 2023
FDA

SODIUM POLYSTYRENE SULFONATE

Approval Date
Aug 12, 2022
FDA

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

Approval Date
Jul 29, 2022
FDA

Phentermine hydrochloride

Approval Date
Apr 14, 2022
FDA

Phentermine Hydrochloride

Approval Date
Apr 14, 2022
FDA

FOLIC ACID

Approval Date
Nov 11, 2021
FDA

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable
3 (100.0%)

The Sunrise SpO2 and Pulse Rate Accuracy Validation Study

Not Applicable
Completed
Conditions
Validation Study
First Posted Date
2022-05-23
Last Posted Date
2022-06-28
Lead Sponsor
Sunrise
Target Recruit Count
12
Registration Number
NCT05386836
Locations
🇧🇪

Respisom, Namur, Belgium

Validation of an Integrated Digital Solution (SUNrise®) Versus Polysomnography for Obstructive Sleep Apnea Diagnosis

Not Applicable
Completed
Conditions
Obstructive Sleep Apnea
First Posted Date
2021-09-27
Last Posted Date
2024-12-06
Lead Sponsor
Sunrise
Target Recruit Count
848
Registration Number
NCT05057975
Locations
🇫🇷

CHU Angers, Angers, France

🇫🇷

Hôpitaux Universitaires de Paris Seine Saint-Denis (HUPSSD, AP-HP),, Bobigny,, France

🇫🇷

Nouvelle clinique Bel-Air, Bordeaux, France

and more 16 locations

Transcutaneous Electrical Stimulation in Obstructive Sleep Apnea

Not Applicable
Completed
Conditions
Obstructive Sleep Apnea
First Posted Date
2021-06-21
Last Posted Date
2023-04-14
Lead Sponsor
Sunrise
Target Recruit Count
42
Registration Number
NCT04932486
Locations
🇧🇪

Respisom, Namur, Belgium

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.